The role of dupilumab in the treatment of eosinophilic esophagitis DOI
Erin Syverson, Eitan Rubinstein, John J. Lee

и другие.

Immunotherapy, Год журнала: 2024, Номер 16(13), С. 845 - 852

Опубликована: Июль 19, 2024

Dupilumab has been approved to treat a variety of atopic disorders and was the first US FDA-approved medication for treatment eosinophilic esophagitis (EoE), initially in May 2022, with expansion use patients as young 1 year age weighing at least 15 kg January 2024. It is fully human monoclonal antibody that inhibits both IL-4 IL-13 signaling, suppressing TH2-mediated proinflammatory cytokines, chemokines IgE implicated EoE pathogenesis. Phase II III trials have demonstrated histologic, endoscopic symptomatic improvement disease activity an overall favorable safety profile. This article will review available clinical trial data real-world efficacy dupilumab EoE.

Язык: Английский

Crafting a Therapeutic Pyramid for Eosinophilic Esophagitis in the Age of Biologics DOI Open Access
Salvatore Oliva, Seema S. Aceves, Noam Zevit

и другие.

Clinical Gastroenterology and Hepatology, Год журнала: 2024, Номер 22(9), С. 1763 - 1769

Опубликована: Сен. 1, 2024

Язык: Английский

Процитировано

2

Emerging therapies for eosinophilic esophagitis DOI
Patrick D. Meek, Brian A. Hemstreet

Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, Год журнала: 2023, Номер 43(4), С. 338 - 348

Опубликована: Фев. 25, 2023

Eosinophilic esophagitis (EoE) is an inflammatory condition of the esophagus that quickly becoming a more recognized cause esophageal dysfunction and dysphagia. The EoE thought to be due response triggered by exposure dietary or environmental antigens. Symptoms may progressive include reflux, nausea, vomiting, dysphagia, reduction in quality life. Both children adults affected. Initial treatments for have focused on elimination diets potentially identify remove triggers, acid suppression with proton pump inhibitors, topical delivery orally administered swallowed corticosteroids. These therapies are often ineffective large proportion patients, leading exploration other approaches focusing cytokines involved response. Most recently, dupilumab, monoclonal antibody targeting IL-4 received approval use patients aged 12 years older EoE. Use dupilumab has seen favorable improvements disease progression symptoms chronic use. Other IL-5, such as mepolizumab, reslizumab, benralizumab currently being studied Therapies key mediators EoE, Siglec-8 (lirentelimab), IL-13 (cendakimab), sphingosine 1-phosphate receptor (etrasimod) evaluated clinical trials.

Язык: Английский

Процитировано

5

Treatment of Pediatric Eosinophilic Esophagitis: Traditional and Novel Therapies DOI

Colby S. Sharlin,

Vincent A. Mukkada,

Philip E. Putnam

и другие.

Current Gastroenterology Reports, Год журнала: 2023, Номер 25(11), С. 289 - 298

Опубликована: Сен. 2, 2023

Язык: Английский

Процитировано

4

Clinical Evaluation of the Child with Eosinophilic Esophagitis DOI

Maureen Bauer,

Nathalie Nguyen, Chris A. Liacouras

и другие.

Immunology and Allergy Clinics of North America, Год журнала: 2024, Номер 44(2), С. 157 - 171

Опубликована: Янв. 9, 2024

Язык: Английский

Процитировано

1

The role of dupilumab in the treatment of eosinophilic esophagitis DOI
Erin Syverson, Eitan Rubinstein, John J. Lee

и другие.

Immunotherapy, Год журнала: 2024, Номер 16(13), С. 845 - 852

Опубликована: Июль 19, 2024

Dupilumab has been approved to treat a variety of atopic disorders and was the first US FDA-approved medication for treatment eosinophilic esophagitis (EoE), initially in May 2022, with expansion use patients as young 1 year age weighing at least 15 kg January 2024. It is fully human monoclonal antibody that inhibits both IL-4 IL-13 signaling, suppressing TH2-mediated proinflammatory cytokines, chemokines IgE implicated EoE pathogenesis. Phase II III trials have demonstrated histologic, endoscopic symptomatic improvement disease activity an overall favorable safety profile. This article will review available clinical trial data real-world efficacy dupilumab EoE.

Язык: Английский

Процитировано

1